{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:27:43Z","timestamp":1787315263572,"version":"build-2736575974"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:00:00Z","timestamp":1758585600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"\n Objective<\/jats:title>\n \n The\n \n BRAF\n V600E<\/jats:sup>\n <\/jats:italic>\n mutation is one of the most common genetic alterations in papillary thyroid cancer (PTC) and is widely recognized as a factor of poor prognosis. Radioactive iodine (RAI) therapy is recommended after thyroidectomy for patients with high-risk level PTC or distant metastatic PTC. However, the association between\n \n BRAF\n V600E<\/jats:sup>\n <\/jats:italic>\n mutation and RAI refractoriness remains controversial and requires additional investigation. This meta-analysis was conducted to evaluate the impact of\n \n BRAF\n V600E<\/jats:sup>\n <\/jats:italic>\n mutation on the curative effect of RAI therapy.\n <\/jats:p>\n <\/jats:sec>\n \n Materials and methods<\/jats:title>\n \n Electronic searches for relevant studies were performed in the databases of PubMed, EMBASE, and the Science Citation Index databases, with publication date after January 2005. The\n 131<\/jats:sup>\n I uptakes status, response to RAI therapy and recurrence of RAI therapy were extracted and compared using meta-analysis.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n We included 14 eligible studies incorporating 2890 PTC patients, of which 1966 were patients with\n \n BRAF\n V600E<\/jats:sup>\n <\/jats:italic>\n mutation. The pooled analysis indicated that\u00a0\n \n BRAF\n V600E<\/jats:sup>\n <\/jats:italic>\n mutation was strongly associated with the loss of iodine avidity (P = 0.0003) in PTC patients, especially in recurrent individuals (P&lt;0.0001). However,\n \n BRAF\n V600E<\/jats:sup>\n <\/jats:italic>\n mutation had no significant association on the clinical response or recurrence rate of RAI therapy (P = 0.27 and P = 0.29, respectively).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n \n This meta-analysis confirmed the role of\n \n BRAF\n V600E<\/jats:sup>\n <\/jats:italic>\n mutation in deterioration of the ability of RAI uptake but provided insufficient evidence to demonstrate that\n \n BRAF\n V600E<\/jats:sup>\n <\/jats:italic>\n mutation might impact the clinical response and recurrence after postsurgical RAI therapy for PTC patients.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.3389\/fendo.2025.1665545","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T04:13:41Z","timestamp":1758600821000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["The effect of BRAFV600E mutation on radioiodine therapy in patients with papillary thyroid carcinoma: a meta-analysis and systematic review"],"prefix":"10.3389","volume":"16","author":[{"given":"Bin","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Xia","family":"Cen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo-Rui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.2719","article-title":"Trends in thyroid cancer incidence and mortality in the United States, 1974-2013","volume":"317","author":"Lim","year":"2017","journal-title":"Jama"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ando.2011.03.025","article-title":"Epidemiology of thyroid carcinoma over the world","volume":"72","author":"Leenhardt","year":"2011","journal-title":"Ann Endocrinol (Paris)"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer","volume":"26","author":"Haugen","year":"2016","journal-title":"Thyroid"},{"key":"B4","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1056\/nejm199801293380506","article-title":"Papillary and follicular thyroid carcinoma","volume":"338","author":"Schlumberger","year":"1998","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-030838","article-title":"BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas","volume":"88","author":"Nikiforova","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-1775","article-title":"The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study","volume":"97","author":"Elisei","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ciresp.2018.02.018","article-title":"BRAF V600E mutation in papillary thyroid cancer and its effect on postoperative radioiodine ((131)I) therapy: Should we modify our therapeutic strategy","volume":"96","author":"Dom\u00ednguez Ayala","year":"2018","journal-title":"Cir Esp (Engl Ed)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.7150\/thno.57689","article-title":"Molecular mechanisms of radioactive iodine refractoriness in differentiated thyroid cancer: Impaired sodium iodide symporter (NIS) expression owing to altered signaling pathway activity and intracellular localization of NIS","volume":"11","author":"Oh","year":"2021","journal-title":"Theranostics"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.4158\/ep-2019-0155","article-title":"Unfavorable responses to radioiodine therapy in N1b papillary thyroid cancer: a propensity score matching study","volume":"25","author":"Liu","year":"2019","journal-title":"Endocr Pract"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3881\/j.issn.1000-503X.2016.03.019","article-title":"Clinical outcome of radioiodine therapy in low-intermediate risk papillary thyroid carcinoma with BRAF(V600E) mutation","volume":"38","author":"Li","year":"2016","journal-title":"Zhongguo Yi Xue Ke Xue Yuan Xue Bao"},{"key":"B11","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/mnm.0000000000000930","article-title":"The BRAFV600E mutation in papillary thyroid microcarcinoma with intermediate-risk to high-risk features: does the mutation have an effect on clinical response to radioiodine therapy","volume":"40","author":"Shen","year":"2019","journal-title":"Nucl Med Commun"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group","volume":"283","author":"Stroup","year":"2000","journal-title":"JAMA"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.2147\/ott.s308910","article-title":"The association between radioiodine refractory in papillary thyroid carcinoma, sodium\/iodide symporter expression, and BRAF (V600E) mutation","volume":"14","author":"Anekpuritanang","year":"2021","journal-title":"Onco Targets Ther"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1530\/eje-10-0290","article-title":"BRAF in primary and recurrent papillary thyroid cancers: the relationship with (131)I and 2-[(18)F]fluoro-2-deoxy-D-glucose uptake ability","volume":"163","author":"Barollo","year":"2010","journal-title":"Eur J Endocrinol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-022-05820-x","article-title":"The genetic duet of BRAF V600E and TERT promoter mutations predicts the poor curative effect of radioiodine therapy in papillary thyroid cancer","volume":"49","author":"Cao","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B18","doi-asserted-by":"publisher","first-page":"785","DOI":"10.3390\/cancers11060785","article-title":"AXL is a novel predictive factor and therapeutic target for radioactive iodine refractory thyroid cancer","volume":"11","author":"Collina","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-0607","article-title":"BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study","volume":"93","author":"Elisei","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.959089","article-title":"Positive BRAFV600E mutation of primary tumor influences radioiodine avidity but not prognosis of papillary thyroid cancer with lung metastases","volume":"13","author":"Huang","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.266044","article-title":"Molecular markers are associated with onset of radioiodine refractoriness in patients with papillary thyroid carcinoma","volume":"64","author":"Laschinsky","year":"2023","journal-title":"J Nucl Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-015-3305-1","article-title":"Noninferior response in BRAF(V600E) mutant nonmetastatic papillary thyroid carcinoma to radioiodine therapy","volume":"43","author":"Li","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.227652","article-title":"The genetic duet of BRAF V600E and TERT promoter mutations robustly predicts loss of radioiodine avidity in recurrent papillary thyroid cancer","volume":"61","author":"Liu","year":"2020","journal-title":"J Nucl Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1677\/erc.1.01119","article-title":"The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+\/I- targeting to the membrane","volume":"13","author":"Riesco-Eizaguirre","year":"2006","journal-title":"Endocr Relat Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1097\/rlu.0000000000002142","article-title":"BRAFV600E mutation does not significantly affect the efficacy of radioiodine therapy in patients with papillary thyroid carcinoma without known distant metastases","volume":"43","author":"Shen","year":"2018","journal-title":"Clin Nucl Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1097\/rlu.0000000000000498","article-title":"BRAFV600E mutation associated with non-radioiodine-avid status in distant metastatic papillary thyroid carcinoma","volume":"39","author":"Yang","year":"2014","journal-title":"Clin Nucl Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1530\/ec-19-0045","article-title":"Clinical significance of the BRAFV600E mutation in PTC and its effect on radioiodine therapy","volume":"8","author":"Zhu","year":"2019","journal-title":"Endocr Connect"},{"key":"B28","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.anorl.2013.01.004","article-title":"BRAF mutation in papillary thyroid carcinoma: predictive value for long-term prognosis and radioiodine sensitivity","volume":"131","author":"Zoghlami","year":"2014","journal-title":"Eur Ann Otorhinolaryngol Head Neck Dis"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-024-14935-4","article-title":"BRAF V600E mutation lacks association with poorer clinical prognosis in papillary thyroid carcinoma","volume":"31","author":"Lai","year":"2024","journal-title":"Ann Surg Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13133645","article-title":"Molecular perspectives in radioactive iodine theranostics: current redifferentiation protocols for mis-differentiated thyroid cancer","volume":"13","author":"Gulec","year":"2024","journal-title":"J Clin Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1177\/107327481402100307","article-title":"BRAF mutations: signaling, epidemiology, and clinical experience in multiple Malignancies","volume":"21","author":"Hall","year":"2014","journal-title":"Cancer Control"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1172\/jci46382","article-title":"Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation","volume":"121","author":"Chakravarty","year":"2011","journal-title":"J Clin Invest"},{"key":"B33","doi-asserted-by":"publisher","first-page":"e120","DOI":"10.1038\/emm.2014.68","article-title":"B-RafV600E inhibits sodium iodide symporter expression via regulation of DNA methyltransferase 1","volume":"46","author":"Choi","year":"2014","journal-title":"Exp Mol Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2012.06.007","article-title":"The sodium iodide symporter (NIS): regulation and approaches to targeting for cancer therapeutics","volume":"135","author":"Kogai","year":"2012","journal-title":"Pharmacol Ther"},{"key":"B35","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1530\/ec-17-0302","article-title":"NIS expression in thyroid tumors, relation with prognosis clinicopathological and molecular features","volume":"7","author":"Tavares","year":"2018","journal-title":"Endocr Connect"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1644562","article-title":"High risk factors, molecular features and clinical management for radioactive iodine-refractory differentiated thyroid carcinoma","volume":"15","author":"Ma","year":"2025","journal-title":"Front Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-2707","article-title":"BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism","volume":"92","author":"Durante","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-0735","article-title":"SWI\/SNF complex mutations promote thyroid tumor progression and insensitivity to redifferentiation therapies","volume":"11","author":"Saqcena","year":"2021","journal-title":"Cancer Discov"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2007.03008.x","article-title":"Molecular characteristics in papillary thyroid cancers (PTCs) with no 131I uptake","volume":"68","author":"Mian","year":"2008","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.7150\/jca.33105","article-title":"The BRAF V600E mutation is a predictor of the effect of radioiodine therapy in papillary thyroid cancer","volume":"11","author":"Ge","year":"2020","journal-title":"J Cancer"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.549882","article-title":"Clinical, pathological, and molecular characteristics correlating to the occurrence of radioiodine refractory differentiated thyroid carcinoma: A systematic review and meta-analysis","volume":"10","author":"Luo","year":"2020","journal-title":"Front Oncol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/cncr.23515","article-title":"Histopathologic characterization of radioactive iodine-refractory fluorodeoxyglucose-positron emission tomography-positive thyroid carcinoma","volume":"113","author":"Rivera","year":"2008","journal-title":"Cancer"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.180240","article-title":"TERT promoter mutation predicts radioiodine-refractory character in distant metastatic differentiated thyroid cancer","volume":"58","author":"Yang","year":"2017","journal-title":"J Nucl Med"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1665545\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T04:13:43Z","timestamp":1758600823000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1665545\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,23]]},"references-count":43,"alternative-id":["10.3389\/fendo.2025.1665545"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1665545","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,23]]},"article-number":"1665545"}}